Michael D Bowman

US Patent:

6586225, Jul 1, 2003

Filed:

Sep 25, 2001

Appl. No.:

09/962834

Inventors:

Michael R. Bowman - Canton MA

Assignee:

Genetics Institute, LLC - Cambridge MA

International Classification:

C12N 964

US Classification:

435226, 435212, 435219, 435325, 4353201, 536 232, 536 231, 536 235

Abstract:

Polynucleotides encoding novel proteases designated âFMH-1â are disclosed. Host cells transformed with such polynucleotides and methods for making FMH-1 proteases are also disclosed. The invention also provides FMH-1 proteases and antibodies that react with them, along with pharmaceutical compositions comprising FMH-1 proteases or polynucleotides encoding FMH-1 proteases. Methods for treating conditions associated with excessive or insufficient apoptosis by administering such pharmaceutical compositions are also disclosed.

US Patent:

7105331, Sep 12, 2006

Filed:

May 16, 2003

Appl. No.:

10/439676

Inventors:

Michael R. Bowman - Westwood MA, US

Assignee:

Genetics Institute, LLC - Cambridge MA

International Classification:

C12N 9/50

US Classification:

435219, 435226, 530350

Abstract:

Polynucleotides encoding novel proteases designated “FMH-1” are disclosed. Host cells transformed with such polynucleotides and methods for making FMH-1 proteases are also disclosed. The invention also provides FMH-1 proteases and antibodies that react with them, along with pharmaceutical compositions comprising FMH-1 proteases or polynucleotides encoding FMH-1 proteases. Methods for treating conditions associated with excessive or insufficient apoptosis by administering such pharmaceutical compositions are also disclosed.

US Patent:

20020086982, Jul 4, 2002

Filed:

Aug 3, 2001

Appl. No.:

09/921994

Inventors:

Michael Bowman - Westwood MA, US

International Classification:

C07H021/02
C07H021/04
C07K001/00
C07K014/00
C07K017/00

US Classification:

536/023100, 530/350000

Abstract:

Novel EBI-3-alt polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length EBI-3-alt proteins, the invention further provides isolated EBI-3-alt fusion proteins, antigenic peptides and anti-EBI-3-alt antibodies. The invention also provides EBI-3-alt nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an EBI-3-alt gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

20020150563, Oct 17, 2002

Filed:

Jan 7, 2002

Appl. No.:

10/040919

Inventors:

Michael Bowman - Canton MA, US
Patricia Lohmar - Belmont MA, US
Nancy Wood - Somerville MA, US

Assignee:

Genetics Institute, Inc

International Classification:

A61K038/43
C07H021/04
C12N009/16
C12P021/02
C12N005/06

US Classification:

424/094100, 435/196000, 435/320100, 435/325000, 435/069100, 536/023200

Abstract:

A novel secreted and glycophosphatidylinositol-anchored protein, GPI-122, is disclosed, as are antibodies that specifically bind to this protein. Polynucleotides encoding GPI-122 are also provided.

US Patent:

20020192779, Dec 19, 2002

Filed:

Jan 7, 2002

Appl. No.:

10/041778

Inventors:

Michael Bowman - Canton MA, US

Assignee:

Genetics Institute, Inc.

International Classification:

C12N009/00
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/183000, 435/069100, 435/320100, 435/325000, 536/023200

Abstract:

A novel secreted protein, BA3.1, is disclosed. Polynucleotides encoding BA3.1 are also provided.

US Patent:

20020193567, Dec 19, 2002

Filed:

Apr 2, 2002

Appl. No.:

10/114893

Inventors:

Kenneth Jacobs - Newton MA, US
John McCoy - Reading MA, US
Edward LaVallie - Harvard MA, US
Cheryl Evans - Germantown MD, US
David Merberg - Acton MA, US
Maurice Treacy - Dublin, IE
Michael Bowman - Canton MA, US
Vikki Spaulding - Danville NH, US
Kerry Kelleher - Marlborough MA, US

Assignee:

Genetics institute, Inc.

International Classification:

C12P021/02
C12N005/06
C07K014/435
C07H021/04

US Classification:

530/350000, 536/023200, 435/069100, 435/320100, 435/325000

Abstract:

Novel polynucleotides and the proteins encoded thereby are disclosed.

US Patent:

20030027139, Feb 6, 2003

Filed:

Mar 29, 2001

Appl. No.:

09/822846

Inventors:

Kenneth Jacobs - Newton MA, US
John McCoy - Reading MA, US
Edward LaVallie - Harvard MA, US
Cheryl Evans - Germantown MD, US
David Merberg - Acton MA, US
Maurice Treacy - Dun Laoghaire, IE
Michael Agostino - Andover MA, US
Michael Bowman - Westwood MA, US
Vikki Spaulding - Lowell MA, US
Gordon Wong - Brookline MA, US
Hilary Clark - San Francisco CA, US
Kim Fechtel - Arlington MA, US
Steven Howes - Cambridge MA, US
Richard Resnick - Somerville MA, US
James Graham - Arlington MA, US

International Classification:

C12Q001/68
C07H021/04
C12N009/00
C12N005/06
C12P021/02

US Classification:

435/006000, 435/069100, 435/183000, 435/320100, 435/325000, 536/023200

Abstract:

Isolated polynucleotides which have been derived from a variety of human tissue sources, and which encode novel secreted proteins, are provided. Also provided are methods for producing proteins using these polynucleotides, and the proteins so produced.

US Patent:

20040234517, Nov 25, 2004

Filed:

Mar 4, 2004

Appl. No.:

10/792280

Inventors:

Michael Bowman - Westwood MA, US
Maximillian Follettie - Belmont MA, US
Hang Chen - Newton MA, US
Cara Williams - Methuen MA, US
Aaron Winkler - Arlington MA, US
Debra Ellis - Lowell MA, US
Wei Liu - Sudbury MA, US

Assignee:

WYETH - Madison NJ

International Classification:

A61K038/48
A61K048/00

US Classification:

424/094630, 514/044000, 514/565000

Abstract:

The present invention provides compositions and methods useful for detecting or treating asthma or other allergic or inflammatory diseases. In one aspect, the methods of the present invention include inhibiting the activity or expression of a component of an arginine metabolic pathway in tissues affected by asthma or other allergic or inflammatory diseases. In many embodiments, the component being inhibited is a cationic amino acid transporter, an arginase, or a component downstream of the arginase. In many other embodiments, the activity or expression of the component is inhibited by an agent that binds to the component. In still many other embodiments, the activity or expression of the component is inhibited by an agent that binds a polynucleotide encoding the component.